Mexico - Delayed Quote MXN

Novavax, Inc. (NVAX.MX)

123.00

0.00

(0.00%)

At close: April 21 at 12:07:04 PM CST

Why the Market Dipped But Novavax (NVAX) Gained Today

Novavax (NVAX) closed at $6.01 in the latest trading session, marking a +0.17% move from the prior day.

Zacks yesterday

NVAX
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Zacks 5 days ago

PFE

MRNA

CVAC
Novavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine Formula

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, Adjuvanted, compared to Pfizer-BioNTech's offering. Despite this positive development, the company's stock performance last week was largely flat, rising 1%, amid broader market fluctuations driven by U.S. restrictions on chip exports to China. The Dow Jones, S&P 500, and Nasdaq all experienced notable...

Simply Wall St. 6 days ago

NVAX
Here's Why Novavax (NVAX) Fell More Than Broader Market

In the latest trading session, Novavax (NVAX) closed at $6.39, marking a -0.31% move from the previous day.

Zacks 7 days ago

NVAX
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 Vaccine Doses in Utah) that showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) targeting the JN.1 strain resulted in fewer and less severe reactogenicity symptoms, when compared with the Pfizer-BioNTech mRNA 2024-2025 vaccine. This real-world study conducted between Septe

PR Newswire 7 days ago

NVAX
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab

The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 vaccine in a recent interview.

Zacks 11 days ago

NVAX
Novavax slides after RFK Jr. casts doubts about COVID vaccine

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit

TipRanks 11 days ago

PFE

NVAX

MRNA
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks 11 days ago

NVAX
Nike, Disney, Novavax: Trending Tickers

Julie Hyman and Josh Lipton take a closer look at some of Thursday's trending tickers on Market Domination. Tariff risks weigh on Nike (NKE) as US President Trump increases the tariff on imports from China to 145%. Entertainment stocks like Disney (DIS), Warner Bros. Discovery (WBD), and Fox (FOX, FOXA) are falling after China cut imports of Hollywood content. Novavax (NVAX) stock plunges after US Health and Human Services Secretary Robert F. Kennedy Jr. questioned the efficacy of the company's vaccines. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 12 days ago

FOX

FOXA

WBD
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 vaccine in an interview with CBS News. The U.S. Food and Drug Administration, an agency that is part of the HHS, missed its deadline last week for deciding on the traditional approval of the vaccine. When asked if the delay resulted from "personnel being shuffled" at the FDA, Kennedy attributed it to the vaccine's composition.

Reuters 12 days ago

NVAX
Sector Update: Health Care Stocks Drop Thursday Afternoon

Health care stocks were falling Thursday afternoon, with the NYSE Health Care Index shedding 4.4% an

PREMIUM
MT Newswires 12 days ago

NVAX

KTTAW
Novavax & RFK Jr., Costco sales, Lovesac earnings: Market Minute

Josh Lipton explores some of the top stories on Yahoo Finance's Market Minute. Novavax (NVAX) shares fell after US President Donald Trump's Secretary of Health and Human Services Robert F. Kennedy Jr. questioned the efficacy of the company's COVID vaccine. Costco's (COST) March comparable sales beat estimates. Lovesac (LOVE) reported fourth quarter results, with sales beating estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 12 days ago

COST

LOVE

NVAX
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks 12 days ago

UTHR

NVAX
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?

Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 12 days ago

NVAX

JAZZ
Novavax (NasdaqGS:NVAX) Announces Leadership Change With New Board Appointments

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board and the appointment of Margaret McGlynn, along with the addition of John Shiver as an independent director, signify a phase of strategic development focused on vaccine innovation. This positive momentum for Novavax was more noticeable against a broader market backdrop where major indexes, spurred...

Simply Wall St. 13 days ago

NVAX
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks 13 days ago

ANIP

NVAX
2 Beaten-Down Stocks That Still Aren't Worth Buying

President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. Consider two examples: Tilray (NASDAQ: TLRY) and Novavax (NASDAQ: NVAX). Tilray's shares have dropped significantly this year and are worth about 58 cents apiece as of this writing.

Motley Fool 14 days ago

NVAX

TLRY
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 16 days ago

NVAX
Novavax, Inc. (NVAX): Among Unstoppable Stocks That Could Double Your Money

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Novavax, Inc. (NASDAQ:NVAX) stands against other unstoppable stocks that could double your money. Generating significant returns and multiplying their money in the stock market remains a primary goal for […]

Insider Monkey 17 days ago

NVAX
FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.

Yahoo Finance 19 days ago

NVAX

JNJ

MRNA

Performance Overview

Return	NVAX.MX	S&P 500 (^GSPC)
YTD	-26.35%	-10.10%
1-Year	+77.95%	+5.53%
3-Year	-87.24%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novavax, Inc. (NVAX.MX)

Why the Market Dipped But Novavax (NVAX) Gained Today

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

Novavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine Formula

Here's Why Novavax (NVAX) Fell More Than Broader Market

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab

Novavax slides after RFK Jr. casts doubts about COVID vaccine

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Nike, Disney, Novavax: Trending Tickers

Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy

Sector Update: Health Care Stocks Drop Thursday Afternoon

Novavax & RFK Jr., Costco sales, Lovesac earnings: Market Minute

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?

Novavax (NasdaqGS:NVAX) Announces Leadership Change With New Board Appointments

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

2 Beaten-Down Stocks That Still Aren't Worth Buying

Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?

Novavax, Inc. (NVAX): Among Unstoppable Stocks That Could Double Your Money

FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS

Performance Overview